header logo image


Page 509«..1020..508509510511..520530..»

COVID-19 Update: Global Longevity and Anti-senescence Therapy Market is Expected to Grow at a Healthy CAGR with top players CohBar, TA Sciences, Unity…

June 10th, 2020 6:48 pm

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Longevity and Anti-senescence TherapyMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Longevity and Anti-senescence Therapy Market Players to battle Covid-19 Impact.

The Longevity and Anti-senescence TherapyMarket report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. It offers detailed research and analysis of key aspects of the Longevity and Anti-senescence Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Longevity and Anti-senescence Therapy market.

Top Leading players covered in the Longevity and Anti-senescence Therapy market report: CohBar, TA Sciences, Unity Biotechnology, AgeX Therapeutics?Inc, PowerVision Inc. and More

Get PDF Sample Report With Impact of COVID-19 on Longevity and Anti-senescence Therapy [emailprotected] https://www.marketinforeports.com/Market-Reports/Request-Sample/83332

The report offers clear guidelines for players to cement a position of strength in the global Longevity and Anti-senescence Therapy market. It prepares them to face future challenges and take advantage of lucrative opportunities by providing a broad analysis of market conditions. the global Longevity and Anti-senescence Therapy market will showcase a steadyCAGR in the forecast year 2020 to 2024.

Product Type SegmentationHemolytic Drug TherapyGene TherapyImmunotherapyOther Stem Cell Therapies

Industry SegmentationHospitalMedical Service InstitutionDrug and Device Sales

Our Complimentary Sample Longevity and Anti-senescence Therapy market Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

Inquire and Get Up to 30% DiscountBy Clicking Here!https://www.marketinforeports.com/Market-Reports/Request_discount/83332

Regions Covered in the Global Longevity and Anti-senescence Therapy Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Longevity and Anti-senescence Therapy Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2024

Highlights of the Report: Accurate market size and CAGR forecasts for the period 2019-2024 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Longevity and Anti-senescence Therapy market Exhaustive research on innovation and other trends of the global Longevity and Anti-senescence Therapy market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

For More Information:https://www.marketinforeports.com/Market-Reports/83332/Longevity-and-Anti-senescence-Therapy-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/83332/Longevity-and-Anti-senescence-Therapy-market

Contact Us:Mr. Marcus KelCall: +1 415 658 9988 (International)+91 84 839 65921 (IND)Email: [emailprotected]Website: http://www.marketinforeports.com

More:
COVID-19 Update: Global Longevity and Anti-senescence Therapy Market is Expected to Grow at a Healthy CAGR with top players CohBar, TA Sciences, Unity...

Read More...

Chinese Company Linked To Tesla Says It Is Ready To Start Making Million-Mile EV Battery – Forbes

June 10th, 2020 6:48 pm

Electric motor on a Tesla Model X full electric car chassis demonstration model on display at ... [+] Brussels Expo in Brussels, Belgium. The platform is fitted with the electric motors for the rear and front wheels and shows the empty space in the middle where the battery packs are fitted on the production models. (Photo by Sjoerd van der Wal)

Concern over the longevity of the batteries powering Tesla electric cars seems to waning as the stock price pushes ever higher, and the Californa-based (for now) carmaker may soon offer drivers even more security in the form of a battery that will last for over a million miles worth of driving.

Chinese battery maker Contemporary Amperex Technology, better known as CATL, which inked a supply deal with Tesla in February, claims it is ready to produce a new battery that will likely outlast an owners time with the car - a situation that has ramifications beyond just driving on electricity.

To be clear, CATLs battery tech doesnt give drivers a million miles on a single charge (that day is still a ways off), rather, the company claims that the battery will work for over 1.2 million driven miles over the course of sixteen years, or about 75,000 miles a year. Driving range will ultimately be determined by the size of the battery pack fitted to the car, but current Tesla models are giving drivers between 250 and 390 miles of range before needing a recharge. depending on configuration and model.

Most car owners in the U.S. drive their cars less than 20,000 miles per year on average. According to the BBC, most EV makers currently warranty their batteries for 60,000 to 150,000 miles.

CATL says it has a two-year contract with Tesla to start putting the new battery in Model 3 units. Terms of the contract were not specified. A company spokesperson told Bloomberg that they stand ready to begin production pending any orders they receive and that the new battery will be a 10% premium over their regular offerings. The BBC reports that CATL is looking to start producing batteries at a plant to be constructed near the German town of Erfurt in 2021. Tesla is also building a new Gigafactory in Germany and hopes to have it up and running in 2021. CATL also indicated they will offer the new batteries to car companies besides Tesla.

After The Car

While a million mile battery sounds impressive, its unlikely that a large number of electric car owners will ever drive their vehicle that distance, and in time, the rest of the vehicle may end up as unusable due to wear and tear, accidents or other service-ending reasons. At the point, the still-useful battery could find service in another role - or possibly in another vehicle as a used electric vehicle market begins to form. The batteries could also be repurposed as home energy storage units or as part of a large-scale battery array that provides power to a community or as power backup for a remote hospital.

The Electric Achilles Heel - For Now

Electric cars (and soon: trucks) continue to gain in popularity, with the now-obvious benefits of impressive performance, quiet operation, less maintenance and low operational costs becoming selling points. But the key component of electric vehicles - the battery - still needs to overcome several hurdles before it can compete squarely with gas-driven machines. Battery costs, charging times, capacity and longevity remain challenging technological problems, and while those problems will likely be solved in the next decade or so, the companies that can up with the solutions stand to reap enormous rewards as all sectors of transportation begin to shift away from fossil fuels. The quest for ever better batteries is driving research and innovation at numerous companies around the globe, with an almost unlimited market as the prize. CATLs battery tech is yet another possible step towards that eventual future.

Want to comment? I post my articles on Twitter, my Facebook page and LinkedIn posts page. Im always interested in your feedback. Thanks for reading and please click Follow below to see new articles when they are posted on Forbes.com.

Go here to see the original:
Chinese Company Linked To Tesla Says It Is Ready To Start Making Million-Mile EV Battery - Forbes

Read More...

Council resumes meetings open to the public – Portsmouth Daily Times

June 10th, 2020 6:48 pm

PORTSMOUTH Portsmouth City Council met Monday for their first meeting open to the press and public since COVID-19 precautions were established in March.

Council members and those present still practiced social distancing while the meeting took place at the Shawnee State University Ballroom. Council dispensed of the reading of the journal for May 26 and excused the absent member of council Tom Lowe.

From the legislative portion of the meeting council passed for first reading an ordinance enacting a new Chapter entitled Discrimination Prohibited, of the Codified Ordinances of the City of Portsmouth establishing a procedure to protect and safeguard the right and opportunity of all persons to be free from all forms of discrimination, including discrimination based on age, race, color, creed, religion, national origin, ancestry, disability, marital status, gender, gender identity or expression, sexual orientation, or physical characteristics and an ordinance amending Section 125.03 (K) Procedures to Determine the Lowest and Best Bid for Construction of Public Improvements of the Codified Ordinances of the City of Portsmouth, Ohio, an Ordinance amending Chapter 171- Fair Housing Practices of the Codified Ordinances of the City of Portsmouth, Other items passed for their respective readings included an Ordinance amending Chapter 171- Fair Housing Practices of the Codified Ordinances of the City of Portsmouth, and an ordinance amending Section 541.08 Ethnic Intimidation of the Codified Ordinances of the City of Portsmouth.

An Ordinance authorizing approval of the consent legislation submitted by Ohio Department of Transportation (ODOT) determining the need for a guardrail project to update Type A end treatments along NHS routes within the corporation limits of Portsmouth and an ordinance authorizing the acceptance of the United States Department of Justice, Office of Justice Programs, Bureau of Justice Assistance funding, under the Edward Byrne Memorial Justice Assistance Grant (EBMJAG) to establish a dedicated account for this grant and to authorize the appropriation of such funding as received, and an ordinance authorizing the acceptance of the United States Department of Justice, and An Ordinance authorizing the employees in the positions of Police Chief and Fire Chief be afforded the same rates for longevity as bargaining unit members within the respective departments were each waived of the three reading rule and were passed by council.

An item added to the agenda to amend the salary ordinance as amended by ordinance no. 87 of 2019 to reflect a 2.75% wage increase for FOP lodge no. 33 and a 2.5% for ASME local 1039 received as of Jan. 1 2020 a 2.75% wage increase retroactive to Jan. 1 2020 for nonunion employees longevity increases to nonunion employees as authorized per ordinance no. 66 of 2017, the addition of parks of recreation director per ordinance no. 71 of 2019 and a wage increase for position of police chief as per 2020 budget ordinance no. 7 and repeal ordinance no. 87 of 2019 was also passed for a first reading by council.

During statements and remarks from citizens regarding items not on the agenda, Sharon Bender addressed council in regards to the death at the Scioto County Jail. Bender said that although the issue is that of the county, people arrested by the Portsmouth Police also go to the jail. There are a lot of questions that need answered, and I think all people within the city of Portsmouth should be concerned that a man has died. I dont really know how more too express other than I think there are irregularities in the photos Ive seen of the man, said Bender. Bender stated that everyone in Portsmouth should be concerned because there is potential for family members of anyone in Portsmouth to find themselves at the jail and that we must demand answers and for the situation to be further addressed. Carrie Duncan also addressed council and voiced her concerns for systematic racism, calling on members of council to use their positions to promote unity.

During his Mayors report, Councilmen Johnson suggested that council be given each a copy of Ms. Duncans questions to answer during next meetings conference in order to follow Sunshine Laws.

Reach: Ivy Potter (740) 353-3101 Extension 1932

2020 Portsmouth Daily Times, all rights reserved

Follow this link:
Council resumes meetings open to the public - Portsmouth Daily Times

Read More...

Fans Claim Queen Elizabeth and Prince Philip Posted a Fake Photo for His Birthday – Showbiz Cheat Sheet

June 10th, 2020 6:48 pm

Celebrities and public figures using Photoshop is a common occurrence. But when its Queen Elizabeth accused of sharing altered photos, its sure to raise a few eyebrows.

The photo in question got posted to the official British royal family Instagram account on June 10 in honor of Prince Philips 99th birthday. Its a milestone birthday even by royal family standards and theyre known for longevity.

The picture of the queen and Philip standing outside Windsor Castle is making rounds on social media not because the Duke of Edinburgh turned 99, but rather because many royal fans are saying its a total fake.

Part of the reason the photo became instantly popular is that Her Majesty and Prince Philip dont take many photos together anymore, especially after the Duke of Edinburgh retired from his public duties in 2017. The picture is the first glimpse of Prince Philip since he was spotted leaving a London hospital on Christmas Eve 2019.

Meanwhile, Queen Elizabeth is still very active in public life and ruling even during the current global pandemic.

At first glance, the Duke of Edinburghs birthday snapshot looks totally normal. He and Queen Elizabeth are standing on the lush, green lawn of Windsor Castle where she and her husband have been holed up since quarantine guidelines became mandatory.

But upon closer inspection, fans are noticing that theres somethingstrange about the picture. Theyre saying it looks like a bad Photoshopattempt.

Look at [the queens] hands its clearly photoshopped. I havea feeling they werent even physically together for this photo, one Facebook userin a royalfamily fan group shared. The more I look at it the more I can see what is wrong withthe photo, another agreed.

The main complaint about the photo is that the shadows on Queen Elizabeth and Prince Philip dont match the sunny background, giving it an odd appearance that seems fake. Could it be that the photo was taken in front of a green screen with the backdrop added later? Maybe.

My guess is that they took the picture indoors and thensuperimposed it over the outdoors of Windsor Castle. Either that or its somesort of 3D photo, one commenter explained.

Others claim the couple looks too healthy in the picture. They are too young in that pic. He is much more frail, another person said. Am I the only one who thinks he had his jacked padded to appear healthier? one follower wondered. Philips hair looks touched up too! added another.

Between the global pandemic and civil unrest, people are feeling very nervous all around the globe. The royal family released the photo partly to celebrate the Duke of Edinburghs birthday and partly to remind the United Kingdom that Her Majesty is still working and still in charge.

Photoshoppedor not, its a lovely photo and positive gesture from the royals.

Read the original here:
Fans Claim Queen Elizabeth and Prince Philip Posted a Fake Photo for His Birthday - Showbiz Cheat Sheet

Read More...

LETTER TO THE EDITOR | Sunday was just the beginning – The Auburn Plainsman

June 10th, 2020 6:48 pm

We are Auburn Students and Community for Change. The purpose of the protest on Sunday, June 7, was to amplify the call to justice for the murder of George Floyd, Breonna Taylor, Tony McDade and the countless Black people who have lost their lives at the hands of police brutality.

We are heartbroken and enraged for every community that has lost someone to the cruelty of both the police and the systems that consistently and unremorsefully uphold the polices reign over Black lives.

Auburn Students and Community for Change would like to thank everyone for attending Sunday's protest and standing in solidarity with the Black community.

We would also like to extend our appreciation to the many people that have contributed to and supported the protest that were unable to be present with us. Your support does not go unnoticed.

Even though the protest on Sunday has ended, the Black Lives Matter movement and Auburn 4 Changes protest against police brutality, discrimination, and racism does not end here. If you care about this movement, we challenge you to take action every day to educate yourself and support organizations working toward equity and justice.

To our Allies:

Get comfortable with being uncomfortable as you stand in solidarity, advocate, and uplift Black voices within our community!

Please stop looking to Black people to fill voids in your knowledge about social and criminal injustice. You have the world wide web to educate yourself. Use it, and in turn, educate your non-Black peers.

Please continue or start calling out your friends, family, coworkers and professors making racist remarks or discriminating against minorities. You have the power to hold your city and University accountable, and to bring about drastic structural change.

By not speaking up you show that you agree. Continue to have discussions with Black people and practice Cultural Humility above all.

To the Black community:

Our voices will no longer be silenced! Our presence will be felt!

This is not a sprint but a marathon. We must continue to support each other and not give space to those who try to create division within our community.

Continue educating yourselves and finding where and how you can contribute to our movement.

We have a long history of Black liberationism and organizing to draw from, and our current mental health is also key for the longevity of our movement, locally and worldwide. Please continue to allow yourself to feel angry and demand change. It is time people are held accountable.

Lastly, remember why we all march. Remember what we fight for.

Yes, we fight for an end to police violence in the Black community. But even more, we fight against the insidious system of racism and oppression that gave rise to the violent policing culture that has existed so long. The insidious system upon which America, this state, and this city were built, and which must be dismantled to bring about a liberated world for all.

We fight against these systems so our children, and their children and their children after that can live in an America that is true to the values it has so long espoused.

The protest on Sunday has ended, but it was just one event. We ask: what are you doing today to combat systems of oppression? What will you do tomorrow? We have a long road ahead of us and a lot of work to do. Lets go.

See the original post here:
LETTER TO THE EDITOR | Sunday was just the beginning - The Auburn Plainsman

Read More...

Why Derrius Guice is the key to the future of the Redskins offense – ClutchPoints

June 10th, 2020 6:48 pm

When Derrius Guice was selected from LSU in the second round by the Washington Redskins back in 2018, his fall from his expected draft position of the first round raised some eyebrows and led to discussions of if his off-field behavior was the cause for that fall.

While he was unable to suit up until 2019 due to a torn ACL suffered during the 2018 preseason, Derrius Guice is very much in the plans for the Redskins moving forward, and he fits perfectly into the plans for the longevity of their offense, being able to team up with quarterback Dwayne Haskins and wide receiver Terry McLaurin.

Derrius Guice suited up for five games in 2019, and even when he came back, he had to deal with incumbent RB Adrian Peterson as the bell cow back even with as long as he has been in the NFL.

Yet, with Derrius Guice coming into 2020 fully healthy, he still has to deal with a full stable of RBs looking for carries.

Besides Peterson and Derrius Guice, the team also has Stanford draftee Bryce Love (who has also dealt with ACL issues), former Seahawks scatback J.D. McKissic, former Tampa Bay Buccaneers back Peyton Barber, former Indianapolis Colts back Josh Ferguson, and rookie draftee Antonio Gibson out of Memphis. While they will most likely move forward with three to four of these backs for the regular season, nothing is promised for any of them.

Derrius Guice is the back with the most to prove on the roster, as his high draft status and pedigree should become the norm for this offense moving forward. His durability and longevity are going to be the biggest determining factors for how successful the Washington offense is this season, but if he remains healthy, he should be able to take over the starting role from Peterson and command lead-back abilities as soon as the first week of the season.

Both Haskins and McLaurin are going into their third seasons in the league, and they have been able to develop a solid rapport in the offense. While both were drafted in the same year after both having attended Ohio State University, so their chemistry was already more advanced than most rookie QB-WR combinations entering the league.

Expectations for the Redskins are low for their 20 season, as they commonly have been over the past five-plus seasons, but that element should play perfectly into the accelerated development of the Redskins on both sides of the ball, but specifically on offense with Derrius Guice.

The offensive line of the Redskins is a bit in shambles, as right guard Brandon Scherff and right tackle Morgan Moses look to be the only solid and incumbent OL starters that will be able to keep Haskins upright this year, which spells disaster. Derrius Guice cant feel comfortable about that situation.

With Haskins blindside currently being protected by projected starters Geron Christian Sr. at left tackle and Wes Schweitzer at left guard, as well as Chase Roullier at center, this offense may revolve around getting the ball out of Haskins hands early in the play and not relying on long-developing route trees and plays, which would help increase Guices involvement.

In his five games last year, Derrius Guice received nine targets, seven of which he caught that went for 79 yards and one of his three touchdowns, including a long of 45 yards. A 77.8 percent catch efficiency percentage is quite high for a running back, even if it is in a vacuum.

Derrius Guice has the hands to be a multi-faceted running back that can serve as a great compliment to what Peterson has provided this team so far, which is a power back that is starting wear down and cannot command 20+ touches each and every game because of needing to keep him fresh. And while Guice cannot be brought back necessarily in full capacity right away so he can try and build up his susceptibility to injuries, it would be in the teams best interest to move forward with him as their lead back from the jump.

Haskins is 24, Derrius Guice is 22, and McLaurin is 23, which is a prime age for this team to try and take advantage of up-and-coming players on their rookie deals. For the Redskins, their defense, which has been the constant focus of early draft picks lately, like Chase Young, Daron Payne, Jonathan Allen, and Montez Sweat, is at a pretty solid spot, especially with strong safety Landon Collins having come over from the divisional rival New York Giants, so the team is now for them to try and maximize their current roster on the offensive side of the ball.

The NFC East, or the NFC Least as it is so affectionately known as, continues to give 8-8 and 7-9 teams hope on a yearly basis to be able to either win the division or sneak into the postseason as the final Wild Card team while the Redskins still project as a sub-.500 franchise for this upcoming season, their chances at progressing up the standings in the division rest very heavily on the health of Derrius Guice, albeit not fully.

Ultimately, Derrius Guice will be looked at as the two-way player that he was drafted to be, even though it has taken much longer than expected to make that kind of impact. His abilities to give the run game another option that can help with outside runs, all while providing a solid screen game/dump-off/split-out option as a receiver will help give this offense another element and if he cannot, there are other options waiting in the wings to take his spot.

Washington will not be great this year again, as their first season under new head coach Ron Rivera will help dictate the future of this franchise and which direction they are heading. For Derrius Guice, while he is no Christian McCaffrey by any means, he can help fulfill that type of role for Rivera and his offense in a way; his role may actually resemble more of what DeAngelo Williams brought to the table for the Panthers. Peterson can have the role Jonathan Stewart owned as the bigger back who was used mainly for between the tackles.

Derrius Guice is the best running back on the roster based on ceiling and potential talent alone whether he realizes and reaches that remains to be seen, but his abilities to break out will dictate the kind of future success the Redskins offense has moving forward.

Here is the original post:
Why Derrius Guice is the key to the future of the Redskins offense - ClutchPoints

Read More...

Evera, A Harvard Consumer Biotech Company, Brings Stem Cell Banking To You – Forbes

June 10th, 2020 12:47 am

Throughout the past decade, consumer biology tests have been all the rage. Companies such as 23andMe and Ancestry DNA have made their test kits accessible to every day Americans. One can screen for anomalies in their genetic code or identify their lineage. With recent advances in stem cell research, a new opportunity within the consumer biology market has appeared. Nabeel Quryshi, Michael Chen and Zeel Patel are three Harvard undergraduates who observed the unmet, rising demand of control over ones stem cells. They worked together to create Evera, the first at-home stem cell banking company. The three Harvard students are joined by the schools world-renowned biology professor, Dr. George Church. The Cambridge, Massachusetts-based company was incubated at the Harvard Innovation Lab, and has former NASA astronaut Scott Kelly as a investor.

Evera cofounders from left to right: Nabeel Quryshi, Michael Chen and Zeel Patel.

Kelly says, "I did a lot of my independent research, consulted with NASA physicians and scientists, and experts in the stem cell for cancer treatment fields. All those discussions and research indicated that this technology has merit."

Frederick Daso: What led you and your team to identify that stem cells could be potentially used to prevent neurodegenerative disease?

Nabeel Quryshi: I wouldn't single out a focus on neurodegenerative diseases. However, over the last decade, there has been a flurry of research around the use of stem cells to treat conditions such as Parkinson's, Dementia, Alzheimer's, etc. People are working on prevention, but there are two main use cases of stem cells currently. One is for treatment (replacement of damaged or lost cells), and the other is disease modeling (being able to model diseases and test the effects of new drugs completely in vitro without having to get a biopsy).

Daso: In the same ways that blood banks function, how did you manage to apply that concept to the storage of stem cells over a long time?

Quryshi: Cord blood banks and academic stem cell banks that use standardized cryopreservation protocols have been around for a while. The main innovation behind Evera was developing technology around the collection and preservation of urine-derived cells.

Daso: Why don't more mothers store their children's cord blood in stem cell banks? Is it mostly due to a price issue, or is there some other factor at play?

Quryshi: From the countless interviews we've done, it seems to be a price issue. Additionally, it's hard to make a sale around the time of birth as families have countless other things to worry about that are more immediate to the birth of a child.

Daso: What would be driving the growth of this market both now and in the future?

Quryshi: The growth of new cutting edge cell therapies is certainly further demonstrating the need for personal cell biobanking. Furthermore, the success of the direct to consumer genetic testing industry (23andMe, Ancestry, etc.) is a significant driver of growth. From the research we've conducted and the customers we have spoken to, individuals who have already taken 23andMe or another genetic test and know what they are at risk for genetically are looking for ways to take tangible action. Evera is that next step. Instead of just understanding what your future genetic risk is, Evera allows you to make a real biological investment in your future health and wellbeing. While knowing you're at risk for saying Parkinson's is excellent, being able to set aside your youngest cells so that one day you may be able to combat the effects of such a disease is terrific.

However, one should note that although the growth and technology coming from the cell therapy and stem cell therapy industry is astonishing, these are still projections. We have yet to see a fully FDA approved therapy that utilizes the specific types of stem cells we use (induced pluripotent stem cells). Nevertheless, by the time such treatments make it to the clinic, your cells will have aged significantly, and thus it makes sense to save them away now.

Daso: Could you walk me through the thought process of figuring out how to extract stem cells from urine? (From what I know, stem cells usually come from other parts of your body!)

Quryshi: Until around 2011/2012, you would have been right. However, utilizing the fantastic technology that comprised Dr. Yamanaka's 2006 Nobel Prize, scientists have been able to convert any cell in the human body to a kind of stem cell called an induced pluripotent stem cell. This cell has the capability of being able to differentiate into any cell type in the human body. We have advanced tech around the conversation of urine-derived cells to these iPSCs.

Daso: How have you designed your D2C service to ensure that a customer's DNA and associated data are not at risk?

Quryshi: We take data and privacy extremely seriously. We are well aware of the concerns people already have to D2C genetics products. To ensure the confidentiality and privacy of your data and sample, we separate your personally identifiable information from sample information and simultaneously use multiple layers of encryption and cryptography. Your sample and associated data cannot be associated with you individually. Furthermore, our facility is monitored 24/7 with top of the line security measures. We believe that your sample is your property.

Daso: What was the turning point during your undergrad to pursue this idea?

Quryshi: Having worked at 23andMe, I was able to get the lucky opportunity to be a part of arguably the world's most successful consumer genetics company. I saw first hand the benefits of providing customers with their genetic risk. Yet, I discovered that merely providing such risk predictions may not be enough led me to found Evera on the notion that tangibly investing in one's future health and wellbeing through cell banking will propel us into the age of personalized medicine.

Daso: How do you leverage your advisory board to navigate regulations and moral hazards in this space?

Quryshi: We have assembled a dream team consisting of experts in stem cell banking and cell therapy. Our co-founders and advisors comprise of professors from Harvard and Stanford, executives from companies such as Verily as well as top grad students and postdocs in stem cell biology from Harvard and Stanford. We work collaboratively to make sure we adhere to all regulations and ensure the secure preservation of our customer's cells.

If you enjoyed this article, feel free to check out my other work onLinkedInand my personal website,frederickdaso.com. Follow me on Twitter@fredsoda, on Medium@fredsoda, and on Instagram@fred_soda.

Original post:
Evera, A Harvard Consumer Biotech Company, Brings Stem Cell Banking To You - Forbes

Read More...

Cancer Stem Cell Therapy Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 – Cole of Duty

June 10th, 2020 12:47 am

A new market report by Market Research Intellect on the Cancer Stem Cell Therapy Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Cancer Stem Cell Therapy sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=237615&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Cancer Stem Cell Therapy manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Cancer Stem Cell Therapy Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=237615&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Cancer Stem Cell Therapy. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=237615&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Cancer Stem Cell Therapy market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Follow this link:
Cancer Stem Cell Therapy Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty

Read More...

Stem Cell Therapy Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Trends, Opportunities and Forecast 2026 – Cole of Duty

June 10th, 2020 12:46 am

A new market report by Verified Market Research on the Stem Cell Therapy Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Stem Cell Therapy sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=COD&utm_medium=007

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Stem Cell Therapy manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Stem Cell Therapy Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=007

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Stem Cell Therapy. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Verified Market Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=007

Customization of the Report:

Verified Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Stem Cell Therapy market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Read the original:
Stem Cell Therapy Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Trends, Opportunities and Forecast 2026 - Cole of Duty

Read More...

USDA revised regulations of GMO and gene edited plants. Here’s what it means. – Genetic Literacy Project

June 10th, 2020 12:45 am

The long-awaited updates from the United States Department of Agriculture (USDA) to its genetically engineered (GE) organism regulation have been issued. This final rule completed a more than 10-year process started back in 2008 to revise regulations promulgated in 1987. This article discusses these new regulations and some of their potential impacts. Overall, the rule ignores concerns raised by some industry, consumer and environmental groups that the new regulations, including an option for developers to self-determine whether their products are regulated, and could lead to adverse environmental and/or agricultural impacts, potential food safety risks, trade disruptions and a lack of consumer acceptance of new food technologies.USDA oversight from 1987 to the present

To understand the USDAs new regulation of GE plants, it is important to know how the agency has regulated GE plants since 1987. USDA regulates the import, interstate movement, and environmental release of GE plants under its legal authority to manage plant pests under the Plant Protection Act. A plant pest is any organism that can directly or indirectly injure, cause damage to, or cause disease in any plants or plant product. Under USDA regulations, a GE plant has been considered a potential plant pest if any of its newly introduced DNA came from an organism on USDAs list of plant pests, or if the method of introducing DNA into the plants genome involved an organism on USDAs list of plant pests. For example, if a GE plant was developed using the plant pest Agrobacterium to introduce new DNA, as many are, it was regulated. However, if the same DNA were introduced using the gene-gun method of transformation, USDA would not regulate the GE plant.

Under those regulations (found at 7 CFR part 340), developers were required to submit their GE plant products to one of three oversight processes before environmental release.

The first process, known as notification, is used to regulate field trials of low-risk GE plants. The applicant provides the USDA with information detailing its trial and the agency has 30 days to decide whether to permit the trial to proceed. As many as 1,000 field trials are authorized yearly using this procedure.

The second process is permitting, which requires a more detailed application for any outdoor planting (e.g., field trial) of higher-risk GE plants. After reviewing the application, USDA may issue a permit authorizing the release. The USDA has issued hundreds of permits since 1987.

The third process involves a petition for non-regulated status, where a developer requests the USDA to determinebased on evidence from field trialsthat the GE plant presents no plant pest risk and no longer requires regulation. The petition process is the primary path to commercialization and more than 140 plants have been deregulated.

For each regulatory process, the USDA is ensuring that the GE plant is not going to become a plant pest and cause harm to agricultural interests.

Up until 2011, every GE plant tested outdoors either submitted a notification or received a permit, and all commercialized plants satisfactorily completed the petition process. Then, in 2011, the USDA established a process whereby GE seed developers could ask the agency whether the GE plants they were developing required regulation, or whether they were exempt because they did not involve any plant pest components. The USDA responded to these Am I regulated? inquiries stating whether the GE plant was not regulated and could be planted without oversight. By the end of 2019, USDA determined that more than 85 plants did not fall within its regulatory authority and are exempt from oversight. So, over the last eight years, we have seen a decrease in how many GE plants USDA regulates.[1]

The new rule (called the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient, (SECURE) Rule), which will be implemented over the next 18 months, applies to organisms produced through genetic engineering, which is defined to include techniques that use recombinant, synthesized, or amplified nucleic acids to modify or create a genome. This broad definition includes classical genetic engineering, which add one or more new genes to organism (transgenics, or what consumers consider GMOs), and newer gene editing techniques such as CRISPR, which can make edits within an organisms existing genome.

While the definition captures all GE plants, the USDA exempts many of them from any oversight. First, it exempts products with a single sequence deletion, substitution, or addition (if the addition is from the plants gene pool). Second, it exempts any GE plant that has the same plant-trait-mechanism of action as any GE plant previous regulated by the USDA. This means that if the USDA previously regulated a GE plant, such as an glyphosate-tolerant variety of corn, a new GE glyphosate-tolerant corn is exempt if it employs the same mechanism of action (meaning it biologically operates the same way to provide tolerance). Developers can self-determine whether they qualify for these exemptions; confirmation of their self-determination from the USDA is not required and the agency need not be informed.

If a GE plant is not exempt, the developer can either: (1) apply for a permit if the GE plant has potential plant pest risks; or (2) seek a Regulatory Status Review (RSR). The RSR starts with an initial 180-day process where the USDA determines if the GE plant has any plausible plant pest risks. That initial RSR step is a closer look at the GE plant than the current am I regulated? process, but less detailed than the process used for petitions for non-regulated status. The USDA stated that the initial review does not require any plant-specific laboratory or field-test data. If the USDA decides there are no plausible risks, it sends a letter to the developer stating the plant is not regulated and publishes the letter on its website. If the USDA cannot conclude that there are no plausible risks, then the developer can either: (1) request that the USDA conduct the second part of the RSR, which is detailed evaluation of potential plant pest risks that can take up to 15 month); or (2) apply for a permit. The more lengthy and detailed RSR evaluation is comparable to the current petition for non-regulated status process and ends in the USDA determining either that the GE plant is not regulated or that it needs a permit. If a developer receives a permit from the USDA, any outdoor planting (e.g. a field trial or a commercial planting) is subject to restrictions to prevent inadvertent release into the environment and any adverse plant pest impacts. These are the same restrictions that virtually all GE plants were subject to prior to 2012 under the notification and permitting processes. Only GE plants that receive permits have any continued USDA oversight.

The exemptions are one worrisome aspect of the new SECURE rule. First, they are not supported by scientific evidence showing that these categories of GE plants do not pose risks. Instead, the USDA states that since a single deletion, substitution or addition produces a plant that could be achieved by conventional breeding methods, and because conventionally bred plants have not raised plant pest risks, gene-edited plants that are the same as products that could be achieved through conventional breeding will not pose plant pest risks. The problem with this argument is that a science-based regulatory system should base its oversight on whether the plant possesses traits that make it a potential plant risks, not the plants method of production. One reason the USDA revised its rules was to focus on the properties of a product, not how it was developed, yet that is the very approach these exemptions enshrine. While many, if not most, plants with a single deletion may not present any plant pest risks, if one does, shouldnt USDA regulate it?

The second concern is that the developer self-determines if its product qualifies for an exemption. This sets up an inherent conflict of interest because developers have financial incentives to determine themselves exempt. While some developers will diligently determine the regulatory status of a GE plant, others may not. In addition, when a developer self-determines its product is exempt, neither the USDA nor the public know that the GE plant is being released into the environment and entering the food supply because there is no requirement to notify the agency of ones self-determination. If the USDA does not know which GE plants are self-determined as exempt, how can it confirm that the determination is correct?

One positive of the new rule is the agencys decision to limit the exemptions to single edits. The USDA reasons that while a single edit mimics a product that can be produced through conventional breeding methods, the same is not true for products with multiple edits. Therefore, if a developer makes two or more edits, the developer must apply for a permit or ask for an RSR. The first gene edited commercial product in the USCalyxts high oleic soybean, which the USDA exempted under the am I regulated? processwould not be exempt under the new rules because it has two edited genes. If most gene-edited products end up having two or more edits, the exemptions may have limited applicability.

While multi-edited products are not automatically exempt, the USDA is likely to find in the initial step of the RSR process that many do not pose any plausible plant pest risk. So the result may be the samethese products are not regulated. However, at least the initial RSR determination (instead of a developer self-determination), is made public, so stakeholders will know which multi-edited products are entering the market.

The USDA states that one goal of its revisions is to provide regulatory relief, and the final rule clearly achieves that. Many GE plants that historically required containment for field trials through either the notification or permitting process will no longer be subject to any substantive regulation. They either will be exempt or deemed to have no plausible plant pest risks through the initial step of the RSR process. What this means in practice is that GE plant developers (both private developers and academic scientists) can conduct field trials without any confinement conditions that ensure the GE plants do not persist in the environment after the trial is completed. The USDA stated in its proposed rule that it hopes developers voluntarily continue confinement measures, but that may or may not happen. GE plants have escaped from field trials with USDA oversight in the past and the likelihood of that happening will only increase without USDA oversight. That could mean new proteins inadvertently entering our food supply before they are deemed safe for human consumption. Experimental GE plants persisting in the environment after a field trial is concluded could also harm non-target organisms. Finally, if an unregulated GE plant escapes from a field trial and enters the export market, it could result in rejection of the US commodity because the experimental plant has not been approved in the importing country.

The final rule also fails to provide needed transparency on GE plants that will be commercialized. The USDA, food industry and consumers will be at the mercy of developers to make public information about products that they have deemed exempt. How will the food industry know which foods contain GE plants to ensure they are complying with export market legal requirements? How will food manufacturers and retailers answer questions from consumers asking whether their products contain ingredients from GE or gene-edited plants? If consumers are unable to access information about which GE plants are commercialized, will they become skeptical about those products and their safety? The lack of transparency inherent in the rule could result in international trade problems and misinformed consumers.

GE plants have provided benefits to farmers, the environment and consumers and are likely to continue to do so in the future. However, the USDA rule could impact the food industrys acceptance of those products and fuel consumer suspicions about biotech crops and foods.

[1] While the USDA is the primary agency regulating GE plants, the FDA and EPA regulate subsets of GE plants. If a GE plant is used for food or feed, the FDA regulates it under a voluntary consultation process set up under the Federal Food, Drug and Cosmetic Act. If a GE plant produces a pesticide, the EPA regulates it as a plant-incorporated protectant under the Federal Insecticide, Fungicide, and Rodenticide Act.

Original post:
USDA revised regulations of GMO and gene edited plants. Here's what it means. - Genetic Literacy Project

Read More...

UNC professor leading project to develop high school science lessons on COVID-19 – The Daily Tar Heel

June 10th, 2020 12:45 am

By integrating real world issues into the classroom, Sadler said students can see how the material theyre learning can translate to bigger picture issues and inform important decisions in their lives, which he hopes is achieved through the instructional materials his research team and partner teachers designed.

While Sadler said his team is still working this summer to develop and refine more lessons to form a coherent instructional unit that teachers can use over the course of a week or two in their classrooms, some early versions of activities have already been tested in a few classrooms.

Sadler said one of the activities that has been created shows how social distancing can impact viral spread through a modeled simulation that allows students to manipulate variables to see likely outcomes. Another activity is intended to help students develop a set of skills that can be used to analyze their information sources.

Sadler said all activities will be developed with enough flexibility to be suitable for both in-person or online instruction, due to the uncertainty of returning to the traditional classroom setting in the fall.

As the materials are used in classrooms, the research team will collect data through questionnaires and surveys to gauge students understandings of COVID-19, their interests and their use of information sources.

Based on his initial findings, Sadler said in general, there was greater student interest in learning about the international health crisis than the business as usual curriculum.

Patty Berge, a career technical education biomedical teacher at East Chapel Hill High School, said she felt it was important to address COVID-19 in the classroom since the virus was impacting students lives so dramatically.

Berge said she saw her students knowledge of the pandemic and its impact on their lives improve as a result of tying her curriculum to COVID-19. In collaboration with fellow biomedical teachers at her school, she said she created a few activities for students to delve into facts about COVID-19, the news surrounding it and ways to prevent outbreaks.

There's so much misinformation and disinformation out there about COVID, that it really is our responsibility to make sure that we're teaching the kids to go to the right resources and find the correct information and get the evidence to support what they're saying versus just repeating what they heard somebody else say, which has been a big issue, Berge said.

Margaret Burns, a science teacher at Jordan High School in Durham, said her students showed interest in learning about COVID-19 and found that a lot of them were doing their own research on the virus.

Like Berge, Burns said she thought it was important to remind students where accurate information can be found. Burns said she showed students the Centers for Disease Control and Prevention website and discussed how to understand its guidance and apply their knowledge.

Its definitely going to be something that we talk about in classes for a really long time, Burns said. It is something that's a shared experience by everyone at this point.

As teachers develop lesson plans this summer, Kimberly Manning, a science teacher at East Chapel Hill High School, said COVID-19 will be a part of her instruction and many others in the fall. While science is perhaps the easiest subject to connect to the pandemic, she said history teachers at her school also addressed it from a historical and social justice perspective.

We will always walk hand in hand with diseases, but we as a people, collectively, we have to be able to deal with it, learn about it, decode it and institute practices that are going to allow us to still live and coexist, Manning said. So, as teachers, as educators, we have to make it a part of what we do.

university@dailytarheel.com

Read more from the original source:
UNC professor leading project to develop high school science lessons on COVID-19 - The Daily Tar Heel

Read More...

Swarm of MILLIONS of gene-hacked mosquitoes will be unleashed across USA to wipe out malaria with death sex – The Sun

June 10th, 2020 12:45 am

MUTANT mosquitoes created in a lab to stop the spread of deadly diseases like malaria will be unleashed across the US this summer.

The gene-hacked bugs, crafted by UK biotech company Oxitec, are designed tokill off or reduce local populations of mosquitoes by mating with them.

3

Mosquitoes carry diseases like dengue, Zika and malaria which are then passed to anyone bitten by the creepy crawlies.

While the technology has shown promise in lab experiments, experts warn the scheme could go horribly wrong out in the wild.

"These strategies hold considerable potential benefits for the hundreds of millions of people impacted bymosquito-borne diseaseseach year," a group of scientists and ethicists wrote in The Conversation.

"However, we are concerned that current government oversight and scientific evaluation of genetically-modified mosquitoes do not ensure their responsible deployment."

3

Oxitec's controversial scheme was in May approved for "experimental use" in Florida and Texas by the US Environmental Protection Agency.

Starting this summer, millions of genetically-modified (GM) male mosquitoes will be released every week over the next two years.

When the lab-bred bugs are released and mate with wild females, their female offspring die.

Only female mosquitoes bite, meaning Oxitec's male-only insects won't spread diseases to people.

What is gene editing?

Here's what you need to know

Over time, repeated, large-scale releases of the modified insects should drive the temporary collapse of wild populations.

This should halt the spread of nasty diseases carried by mosquitoes, potentially saving thousands of lives.

Mosquito-borne illnesses like malaria are on the rise in the southern United States as climate change pushes bug populations up from South America.

Scientists are concerned about the lack of oversight for Oxitec projects in Florida and Texas.

For its part, Oxitec said in a statement that the article is The Conversation contained "a number of false or baseless claims".

3

The company has run into trouble before.

In Brazil, an Oxitec project spectacularly backfired after millions of the GM bugs were released into neighbourhoods in Jacobina.

Some scientists believe the project accidentally created a super-resistant mosquito species that's tougher to kill than before.

Oxitec's work has been heavily criticised by Friends of the Earth, a charity dedicated to protecting the environment.

Back in 2012, Friends of the Earth's Eric Hoffman said: "Trials of its mosquitos must not move forward in the absence of comprehensive and impartial reviews of the environmental, human health and ethical risks."

In a statement at the time, Friends of the Earth said: "The GM mosquitoes are intended to reduce the wild population by mating with naturally occurring mosquitoes and producing progeny which dont survive, thus reducing the population and therefore the transmission of the tropical disease dengue fever.

"The company has been widely criticised for putting its commercial interests ahead of public and environmental safety.

"Its first releases of GM mosquitoes took place controversially in the Cayman Islands, where there is no biosafety law or regulation.

"Oxitec staff have been closely involved in developing risk assessment guidelines for GM insects worldwide, leading to concerns about lack of independent scrutiny and conflict of interest."

LOST AND FOUNDLost Roman city revealed using radar uncovering temple, streets and sewers

AIR FAIR?Samsung invents Apple AirPods rivals that look like tiny BEANS in your ears

PLAN IT!How to see planets Jupiter, Saturn AND Mars rising in sky tonight with naked eye

SPACE STORMSaturn has a mystery 'mega storm' shaped like a perfect hexagon

Exclusive

PLAY TIMEPS5 design revealed? Stunning 'first look' images show leaked Sony sketches in 3D

OUT OF JUICEDelete THESE 22 dodgy apps to save your phone's battery life

In other news, Nasa could create "GM astronauts" designed to be super-strong and feel no pain.

Scientists are trying to make grey squirrels extinct in Britain through genetic engineering.

And, breeding "super-cows" that fart less is the latest bonkers plot to halt climate change.

We pay for your stories! Do you have a story for The Sun Online Tech & Science team? Email us at tech@the-sun.co.uk

Read more:
Swarm of MILLIONS of gene-hacked mosquitoes will be unleashed across USA to wipe out malaria with death sex - The Sun

Read More...

China Could Have Coronavirus Vaccine for Emergency Use As Early As This Autumn, Expert Says – Science Times

June 10th, 2020 12:45 am

Zhong Nanshan, China's top respiratory expert who discovered the SARS 2003, now plays a key role in the national COVID-19 policy. He said that it is impossible for any nation to reach herd immunity as it will cost millions of lives.

Nanshan estimates that 60% to 70% of the country's populationto be infected by the virus, which can cause a 30 to 40 million death toll.

That means the only way to defeat COVID-19 is to vaccinate all people. He said that vaccines for use in emergencies would be available as early as this autumn, but it could take at least two years for large-scale use.

It is similar to what Anthony Fauci, head of US National Institute of Allergy and Infectious Diseases, said that 100 million doses of the vaccine might be ready before the year ends and the clinical trials.

Last month, the Chinese Center for Disease Control and Prevention's head, Gao Fu, said that they are already drafting guidelines to determine the individual eligible to receive the vaccine when to take them, and what qualifies an emergency use.

Presently, there are five vaccines under clinical testing in China. One of them is developed by the Beijing Institute of Biological Products, published in its preclinical data on the journal Celllast Saturday.

According to South China Morning Post, its data indicates that the vaccine administered in the macaques, which uses an inactivated pathogen, induced high levels of antibodies that protect the body and provided high-level protection against the SARS-CoV-2, the virus that causes COVID-19.

The researchers administered the vaccine twice a day on day zero and day 14 of the experiment, while a placebo group was only given saline. By the end of day 24, all of the macaques are now exposed to COVID-19.

Throughout the seven-day evaluation period after immunization, they found that the placebo group maintained a high viral load. Meanwhile, swabs are taken from the vaccinated macaques, which showed a peak on viral load by the fifth day and significantly waned by the seventh day.

All animals exposed to the coronavirus were euthanized on the seventh day for pathological examination. Those macaques in the low-dose and high-dose have not shown any detectable viral load, unlike those in the placebo group.

The researchers said that the results of their study demonstrated that "both low-dose and high-dose vaccines are highly efficient in defending against SARS-CoV-2 in macaques without observed antibody-dependent enhancement of infection."

Read Also: Sinovac 99% Confident that 'CoronaVac' Will Work Effectively Against Coronavirus

Aside from the vaccine being developed under the Beijing Institute of Biological Products, its parent company, the China National Biotec Group, said that it was focusing on developing an inactivated vaccine. The company was experienced in that field, and because this type of vaccine can be safely produced, said chairman Yang Xiaoming who told the news portal Thepaper.cn.

Moreover, another subsidiary of the company, the Wuhan Institute of Biological Products, is now on its human trials on using another inactivated vaccine. They have built biosafety production facilities to produce 200 million vaccines each year.

Additionally, they are also developing vaccines that include a recombinant protein vaccine that uses genetic engineering. However, this is not the main priority for the group.

With all these vaccines underway, Shanghai vaccine expert Tao Lina warns that these vaccines could have advantages and disadvantages, and it is still early to say which type will be ready to use first.

Read More: Chinese Doctors Claim they Found New COVID-19 Cure that Can Stop Coronavirus from Spreading Even Without Vaccines

Read the rest here:
China Could Have Coronavirus Vaccine for Emergency Use As Early As This Autumn, Expert Says - Science Times

Read More...

Does China Have A Coronavirus Vaccine? Expert Says One Could Be Available Within Months – International Business Times

June 10th, 2020 12:45 am

KEY POINTS

Chinas top respiratory expert said Tuesday a vaccine for the coronavirus could be ready as early as autumn for emergency use, months earlier than the timeline envisioned by U.S. experts. The comments came amid a Harvard University study that found the virus began circulating in China much earlier than previously suspected.

Zhong Nanshan, former president of the Chinese Medical Association and current the editor-in-chief of the Journal of Thoracic Disease, said guidelines are being drafted to determine who will get the vaccine first and when, along with what would constitute emergency use.

Dr. Anthony Fauci, head of the U.S. National Institute of Allergy and Infectious Disease, has said 100 million doses of a vaccine could be ready by the end of the year even before trials on safety and efficacy are completed.

China has spent a reported $703 million on the development of a vaccine, with five currently undergoing testing. Several others developed elsewhere in the world also are undergoing trials, setting up a global competition akin to the space race.

The journal Cell on Saturday published a preliminary study of a vaccine developed by the Bejing Institute of Biological Products that effectively blocked infection in rhesus monkeys. Development of an effective vaccine by China likely would help deflect criticism of the countrys early handling of the outbreak.

Another vaccine developed by the Wuhan Institute of Biological Products is in the midst of human trials. Both vaccines use inactivated viruses. Research also is focused on other techniques including genetic engineering.

Zhong said without a vaccine, death tolls will continue to mount. By midmorning Tuesday, more than 407,000 people had died worldwide from COVID-19 -- more than a quarter in the United States alone.

Natural immunity needs 60- to 70% of a countrys population to be infected by the novel coronavirus, which could cause a death toll of 30 [million] to 40 million, Zhong told the South China Morning Post. The [only] solution is still mass vaccination.

He added: Large-scale vaccination will take one to two years. The new vaccine can be used in an emergency as early as this autumn or the end of the year.

China rejected findings by Harvard University that coronavirus began circulating in Wuhan as early as August by examining satellite images of hospital parking lots. Chinese Foreign Ministry spokesman Hua Chunying called the conclusions preposterous, but the researchers said the findings line up with the recent recognition that gastrointestinal symptoms are a unique feature of COVID-19 disease and may be the chief complaint of a significant proportion of presenting patients.

China has maintained the infection emerged in November but has been sharply criticized for suppressing information in the initial stages of the pandemic.

Follow this link:
Does China Have A Coronavirus Vaccine? Expert Says One Could Be Available Within Months - International Business Times

Read More...

Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital – Yahoo Finance

June 10th, 2020 12:45 am

GAITHERSBURG, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital. Taking place on Tuesday, June 9 at 11:30 a.m. EDT, the panel will discuss COVID-19 vaccines. The conversation will consider the complex path from lab to clinical trials, the impact of the evolving science on candidate development and consider how collaboration will bring life-saving vaccines to the world.

Details for the panel are as follows:

About Novavax

Novavax, Inc. (NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit http://www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

InvestorsNovavax, Inc. Erika Trahanir@novavax.com240-268-2022

WestwickeJohn Woolfordjohn.woolford@westwicke.com443-213-0506

MediaBrandzone/KOGS CommunicationEdna Kaplankaplan@kogspr.com617-974-8659

See the original post:
Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital - Yahoo Finance

Read More...

Eight Research Projects Receive Funding from Manning Fund for COVID-19 Research – University of Virginia

June 10th, 2020 12:45 am

A recent gift of $1 million from the Manning family, strong supporters of the University of Virginia, established The Manning Fund for COVID-19 Research, designed to support the Universitys practically oriented research on COVID-19-related topics that can be acted upon quickly and have commercial potential.

More than 50 proposals were received from UVA faculty for projects related to developing COVID-19-related solutions.

The offices of the Provost and the Vice President for Research, which co-manage the fund, havefunded eight proposals that support improved antibody testing, vaccine development and improving patient outcomes.

These researchers showed they had both great ideas for conquering COVID-19, and a solid plan for how to accomplish their goals, said Melur Ram Ramasubramanian, vice president for research. We couldnt be more pleased with the projects proposed and their potential impact.

Many of our researchers have set current and pressing projects aside to redirect their energies to COVID-19, said Liz Magill, the Universitys provost. Were grateful that the Manning Fund has enabled this critical research that takes advantage of the cross-disciplinary networks UVA has nurtured over the past few years.

I want to thank the entire research team and administrationfor their acute sense of urgency and entrepreneurship to come up with these helpful solutions to the COVID crisis. They set short term goals and achieved them, said local businessman and investor Paul Manning. I am very grateful.

A rundown of the selected projects:

IgG to SARS-CoV-2 With ImmunoCAPJeffrey Wilson, School of Medicine, Asthma, Allergy & Immunology

Jeffrey Wilson and his team plan to develop a novel assay to measure antibodies to SARS-CoV-2, taking advantage of the lmmunoCAP platform and producing a quantitative readout of how much IgG is present instead of just a yes or a no, as is common in current commercial systems. This has implications in developing an understanding of the likely attachment sites of the virus and accelerating the development of effective vaccines.

A COVID-19 Killed Whole Cell Genome Reduced E. coli Fusion Peptide Subunit VaccineSteven Zeichner, School of Medicine, Pediatrics

A vaccine for COVID-19 is urgently needed to control the pandemic. Steven Zeichner and his team aim to develop a vaccine that helps the body develop antibodies directed against a specific fusion peptide found on the surface of SARS-CoV-2 virus as a component of its spike protein. The novelty of this project is the use a modified E. coli bacterial surface to display this peptide and help the body develop specific antibodies against it. When the real virus enters the body due to infection, the body can recognize this fusion peptide and neutralize the virus.

We expect the results from this project can be quickly translated into a safe, inexpensive, scalable, and effective vaccine appropriate for pandemic response globally, enabling an end to the COVID-19 pandemic not only in developed countries, but around the world, said Steven Zeichner.

Targeted Antibodies From Convalescent Plasma to Protect Against COVID-19Peter Kasson, School of Medicine, Molecular Physiology & Biomedical Engineering

Individuals vary substantially in their antibody response to COVID-19, both in amount and type of antibodies produced. Peter Kassons team aims to purify the serum from recovered patients and identify specific antibodies that are most potent against SARS-CoV-2 and to produce concentrated amounts of these target specific antibodies for the treatment of patients with increased potency.

Novel Reagents to Improve Testing for COVID-19 AntibodiesJames Zimring, School of Medicine, Pathology

The goal of James Zimring and his team is to develop novel testing reagents to eliminate the problem of cross-reactivity with common coronaviruses and develop a neutralization reagent that can be added to any serological assay and any analytic platform for antibody testing, which will eliminate signal from other non-COVID-19 antibodies and improve the accuracy of the test significantly.

Adenosine A2A Receptor Agonists in the Prevention of COVID-19-Related Lung Injury and Systemic Inflammatory ResponsesKenneth Brayman, School of Medicine, Surgery & Molecular Physiology, Infectious Diseases

The main cause of death in COVID-19 is acute respiratory distress syndrome, which is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. Kenneth Brayman and his team aim to test the use of Adenosine A2AR agonists to reduce the mortality associated with COVID-19. This immunotherapy is expected to be used preemptively, in the asymptomatic phase to prevent onset of COVID-19 or in the symptomatic phase, to reverse progression.

Isolation and Identification of Novel T-cell Receptors Responsive to SARS-CoV-2 for the Genetic Engineering of Third-Party T-cells for Off-the-Shelf Therapeutic UseDaniel Lee, School of Medicine, Hematology/Oncology, Pediatric

Daniel Lee and his team plan to study the T-cell-based immune response from patients who have been infected SARS-CoV-2 to identify viral specific T-cell receptors with the future goal of genetically engineering third-party, allogeneic T-cells with the responsive T-cell receptor, thereby producing an off-the-shelf cellular therapeutic bank for the treatment of subsequent infected patients experiencing severe symptoms. This cell therapy would be especially beneficial for immunocompromised patients infected with COVID-19.

Mass Cytometry to Identify Biomarkers for COVID-19 Severity and Response to JAK InhibitionHema Kothari, School of Medicine, Medicine & Cardiovascular Medicine

Cytokine storm in patients has been linked to COVID-19 disease severity. Hema Kotharis team aims to develop a customized diagnostic biomarker assay for early identification of those at risk of a cytokine storm and improve patient outcomes by taking timely action to block cytokines.

COVID-19: Big Data and Analytics for Early Detection of Cardiorespiratory DeteriorationRandall Moorman, School of Medicine, Medicine, Biomedical Engineering and Molecular Physiology and Biological Physics

Randall Moormans team at UVA Center for Advanced Medical Analytics plans to apply artificial intelligence and big data techniques to the problem of acute and unsuspected clinical deterioration of SARS-CoV-2-infected patients, with the goal to provide continuous risk estimation of imminent deterioration using mathematical analysis of readily available clinical and monitoring data.

Originally posted here:
Eight Research Projects Receive Funding from Manning Fund for COVID-19 Research - University of Virginia

Read More...

Optogenetic market 2020: Future Analysis and know what to expect from this Industry along with analysis Global Trends, Industry Growth, Top Company…

June 10th, 2020 12:45 am

Optogenetic Market research added by the insight partners, offers a comprehensive analysis of growth trends prevailing in the global business domain. This report also provides definitive data concerning market, size, commercialization aspects and revenue forecast of the Optogenetic industry. In addition, the study explicitly highlights the competitive status of key players within the projection timeline while focusing on their portfolio and regional expansion endeavours.

This report on Optogenetic Market delivers an in-depth analysis that also comprises an elaborate assessment of this business. Also, segments of the Optogenetic Market have been evidently elucidated in this study, in addition to a basic overview pertaining to the markets current status as well as size, with respect to the profit and volume parameters. The study is ubiquitous of the major insights related to the regional spectrum of this vertical as well as the companies that have effectively gained a commendable status in the Optogenetic Market.

Get the inside scope of the Sample report @https://www.theinsightpartners.com/sample/TIPRE00004718/

MARKET INTRODUCTIONOptogenetic is the biological technique in which light is used to control the cell in living tissue, it is emerging technique. The optogenetics helps to understand the normal and abnormal functioning of brain and used to treat the neurological disorder. In Optogenetics light and genetic engineering is used to control the cell activity and neurons activity. Optogenetics is used to treat the retinal disease, hearing loss, memory disorder.

Key Competitors In Optogenetic Market areCoherent, Inc., Thorlabs, Inc., Cobalt International Energy, Inc., Scientifica, Laserglow Technologies, Gensight Biologics, Jackson Laboratories, Regenxbio Inc., Circuit Therapeutics, Inc., Bruker and Others

MARKET SCOPE

The Global Optogenetics Market Analysis to 2027 is a specialized and in-depth study with a special focus on the global medical device market trend analysis. The report aims to provide an overview of optogenetics market with detailed market segmentation by product type, application, and geography. The global optogenetics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Optogenetics market players and offers key trends and opportunities in the market.

Market segmentation:

By Product Type (Actuators, Sensors, Light Instruments);

By Application (Retinal Disease Treatment, Neuroscience, Cardiovascular Ailments, Pacing, Hearing Problem Treatment)

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

Key Questions Answered

How big will the market for Optogenetic be in 2027? What is the current CAGR of the Optogenetic Market? Which product is expected to have the highest market growth? Which application should be used to win a large part of the market for Optogenetic ? Which region is likely to offer the most opportunities on the Optogenetic Market? Will the market competition change in the forecast period? Who are the main players currently active in the global Optogenetic Market? How will the market situation change within the coming years? What are the usual commercial tactics for players? What is the growth perspective of the global Optogenetic Market?

Answering these types of questions can be very useful for gamers to clear up their doubts as they implement their strategies to grow in the global Optogenetic Market. The report provides a transparent picture of the actual situation in the global Optogenetic Market so that companies can work more effectively. It can be tailored to the needs of readers to better understand the global market for Optogenetic.

Click here to buy full report with all description:-https://www.theinsightpartners.com/buy/TIPRE00004718/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

More here:
Optogenetic market 2020: Future Analysis and know what to expect from this Industry along with analysis Global Trends, Industry Growth, Top Company...

Read More...

MIT Engineers Developed an Interesting Method to Extend the Shelf Life of Foods – Somag News

June 10th, 2020 12:45 am

Benedetto Marelli and his teammates at MIT have discovered a method to naturally prolong the shelf life of foods. In the method, it was discovered that coating food with silk had a serious effect.

Benedetto Marelli, who worked as an assistant professor at the environmental engineering department at MIT, came across a book about the use of silk one day by chance while doing his post-doctoral study at Tufts University. When asked for each set to contain silk in the cooking contest for the universitys laboratory, Marelli accidentally forgot some strawberries wrapped in silk on her counter.

Realizing that the strawberries that were interacting with silk were still edible when she returned almost a week later, Marelli observed that the other strawberries were already spoiled. This situation had a shock effect on the researcher who had previously studied the biomedical applications of silk. Marelli realized that she could find a solution to the problem of food waste with this situation that she discovered by chance and started to work.

Benedetto Marelli, who is an associate professor at MIT, has decided to seek help from different scientists in this regard. Cambridge Crops, which includes these scientists, wanted to test and expand Marellis discovery.

The company aimed to develop products that would extend the shelf life for all easily perishable foods. Thanks to this discovery of the company, it is expected that the shelf life of the food will be prolonged and a solution to the problem of waste, which is of great importance. As a result, it will be possible to reach fresh food more easily.

As you know, while 10% of the worlds population is struggling with hunger, one third of the global food stock is unconsciously wasted every year. Food waste; It is a fact that it has a social and economic impact in developed and developing countries. Although many different technologies that we come across offer us solutions that will prolong the life of fresh foods, most of these solutions contain risks such as playing genetics with foods, and packaging materials and environmental hazards. We can say that this is often accompanied by high costs.

Marelli considers this situation as follows: To date, the vast majority of solutions developed on agricultural technologies and food have been based on genetic engineering, mechanical engineering, artificial intelligence, or computer science. However, nano materials and bio materials can be preferred instead.

According to Marelli, the use of silk can be an excellent opportunity for many problems faced by the food industry, and it can increase the shelf life of the foods without the need to change their essence. Marelli also stated that the food will not change in any way thanks to the coating of silk with flavors, smells and tissues. Allegedly, this practice can naturally increase the shelf life of foods by up to 200%.

Read more:
MIT Engineers Developed an Interesting Method to Extend the Shelf Life of Foods - Somag News

Read More...

Coronavirus vaccine could be ready for emergency use within months, says Chinese expert Zhong Nanshan – Yahoo Singapore News

June 10th, 2020 12:45 am

China could have a Covid-19 vaccine for use in emergencies as early as this autumn, according to the countrys top respiratory expert, Zhong Nanshan.

Zhongs estimate echoed last months comments by Gao Fu, head of the Chinese Centre for Disease Control and Prevention, that it was drafting guidelines to determine who would be eligible to receive the vaccine, when to take them, and what would constitute emergency use.

The head of the US National Institute of Allergy and Infectious Diseases, Antony Fauci, has made similar comments, saying 100 million doses might be ready by the end of the year even before the end of clinical trials.

Zhong said herd immunity without intervention could not be achieved without a high death toll, making inoculation the only feasible means of gaining herd immunity.

Natural immunity needs 60 to 70 per cent of a countrys population to be infected by the novel coronavirus, which could cause a death toll of 30 to 40 million, Zhong told a live event hosted by tech giant Baidu. The [only] solution is still mass vaccination.

[Herd immunity] still depends on the development of vaccines. Large-scale vaccination will take one to two years. The new vaccine can be used in an emergency as early as this autumn or the end of the year.

Five vaccines developed by Chinese scientists are undergoing human trials, according to a government white paper published on Sunday.

One of the candidate vaccines, developed by the Beijing Institute of Biological Products, published its preclinical data on the journal Cell on Saturday.

The data shows that in macaques the vaccine, which uses an inactivated pathogen, induced high levels of antibodies that defend the body and provided a highly efficient protection against Sars-CoV-2, the virus that causes Covid-19.

The macaques were immunised twice on day zero and day 14, while a placebo group was given saline.

On day 24, all the macaques were exposed to Sars-CoV-2.

The placebo group maintained a high viral load throughout the seven-day evaluation period after the exposure, but swabs taken from the vaccinated macaques showed that their viral load peaked on the fifth day and was significantly lower by day seven.

On the seventh day after exposure to the virus, all animals were euthanised for pathological examination.

Five Chinese vaccines are undergoing human trials. Photo: AFP

No macaques in the low-dose and high-dose groups had a detectable viral load in the lung lobes, unlike the placebo group.

Taken together, all these results demonstrated that both low-dose and high-dose [vaccines] conferred highly efficient protection against Sars-CoV-2 in macaques without observed antibody-dependent enhancement of infection, the researchers wrote.

Yang Xiaoming, chairman of China National Biotec Group, the parent company of the Beijing Institute of Biological Products, told news portal Thepaper.cn last month that the group was focusing on developing an inactivated vaccine because it was experienced in this field and they could be produced safely.

Another subsidiary, the Wuhan Institute of Biological Products, is conducting human trials on another inactivated vaccine. The group has built high biosafety production facilities that can produce 200 million vaccines a year.

The group is also developing vaccines that use other techniques including a recombinant protein vaccine that uses genetic engineering but these are a lower priority.

Shanghai vaccine expert Tao Lina said different vaccine technologies had their advantages and disadvantages and it was still early to tell which type of vaccine would be ready to use first.

Inactivated ones usually need two or three doses while other technologies might need only one dose. Vaccines using DNA or RNA technology are likely to enter trials later than inactivated vaccines, but it is easier to expand production capacity for these, Tao said.

Story continues

Read the original:
Coronavirus vaccine could be ready for emergency use within months, says Chinese expert Zhong Nanshan - Yahoo Singapore News

Read More...

Semiconductor Laser Therapeutic Equipment Market Growth, Size, Opportunities and Analysis Forecast 2020 – 3rd Watch News

June 10th, 2020 12:44 am

The latest research report on the Semiconductor Laser Therapeutic Equipment market is an in-depth examination of this business sphere and is inclusive of information pertaining to vital parameters of the industry. The report provides details about the prevailing market trends, market share, industry size, current renumeration, periodic deliverables, and profits projections over the forecast timeframe.

Request a sample Report of Semiconductor Laser Therapeutic Equipment Market at:https://www.marketstudyreport.com/request-a-sample/2470854?utm_source=3wnews.org&utm_medium=TS

An elaborate documentation of the Semiconductor Laser Therapeutic Equipment market performance during the analysis period is entailed in the report. Insights regarding the driving factors which will influence the market dynamics, alongside the growth pattern followed by the industry over the forecast period are presented. The report further focusses on analyzing the challenges existing in the market and growth prospects which define the business vertical over the forthcoming years.

Key highlights of the Semiconductor Laser Therapeutic Equipment market report:

Revealing the geographical landscape of the Semiconductor Laser Therapeutic Equipment market:

Summary of regional analysis presented in the Semiconductor Laser Therapeutic Equipment market report:

An exhaustive survey of Semiconductor Laser Therapeutic Equipment market with respect to product type and application scope:

Product scope:

Product types: Opthalmology, Dermatology, Gynecology, Dentistry, Urology, Cardiovascular and Others

Major pointers mentioned in the report:

Ask for Discount on Semiconductor Laser Therapeutic Equipment Market Report at:https://www.marketstudyreport.com/check-for-discount/2470854?utm_source=3wnews.org&utm_medium=TS

Application scope:

Application segmentation: Family Using, Beauty Using and Medical Using

Insights entailed in the report:

Other takeaways from the Semiconductor Laser Therapeutic Equipment market report:

Elucidating details about the competitive topography of the Semiconductor Laser Therapeutic Equipment market:

Prominent players of the industry: Sirona Dental Systems GmbH, WON TECH, Lumenis Inc., PHYSIOMED ELEKTROMEDIZIN AG, Biolase, Dornier MedTech GmbH, Cutera, IRIDEX Corporation, Quanta System S.p.A, Cynosure, L.H.H. Medical, Shenzhen Tianjiquan, Zhengan Medical, Shandong Shensi, Medicen, Guangdun, Kangjiantong, Wuhan HNC, Helsen, Transverse Industries and Shenzhen GSD

Key parameters included in the report which define the competitive landscape:

The Semiconductor Laser Therapeutic Equipment market report also emphasizes on major industry aspects like market concentration ratio.

For More Details On this Report:https://www.marketstudyreport.com/reports/global-semiconductor-laser-therapeutic-equipment-market-growth-2020-2025

Some of the Major Highlights of TOC covers:

Development Trend of Analysis of Semiconductor Laser Therapeutic Equipment Market

Marketing Channel

Market Dynamics

Methodology/Research Approach

Related Reports:

1. Global Veterinary Monitoring Devices Market Growth 2020-2025Veterinary Monitoring Devices market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market.Read More: https://www.marketstudyreport.com/reports/global-veterinary-monitoring-devices-market-growth-2020-2025

2. Global Collagen Wound Dressings Market Growth (Status and Outlook) 2020-2025Collagen Wound Dressings Market Report covers a valuable source of perceptive information for business strategists. Collagen Wound Dressings Industry provides the overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elegant description of the value chain and its distributor analysis.Read More: https://www.marketstudyreport.com/reports/global-collagen-wound-dressings-market-growth-status-and-outlook-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/europe-animal-healthcare-market-analysis-and-demand-with-forecast-overview-to-2026-2020-06-08

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

More here:
Semiconductor Laser Therapeutic Equipment Market Growth, Size, Opportunities and Analysis Forecast 2020 - 3rd Watch News

Read More...

Page 509«..1020..508509510511..520530..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick